💬In plain words
What the trial is, and whether it could suit you
Siewert type II/III gastroesophageal junction (GEJ) adenocarcinoma is a challenging malignancy located at the anatomical transition between the esophagus and stomach. Due to its complex anatomical location and mixed biological characteristics of esophageal and gastric cancers, the optimal surgical strategy remains controversial. Current surgical approaches vary in terms of operative access, extent of resection, and lymph node dissection. Although minimally invasive laparoscopic and integrated robotic surgery have demonstrated potential advantages in improving perioperative outcomes, limitations remain when managing complex procedures involving both abdominal and mediastinal fields.
Split-type robotic surgical systems, characterized by independently movable robotic carts, provide greater flexibility in robotic arm positioning and may overcome some limitations associated with conventional
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria:
1. Age between 18 and 80 years, inclusive, regardless of sex.
2. Histologically and/or cytologically confirmed Siewert type II or type III gastroesophageal junction tumor, with clinical staging according to AJCC 8th edition TNM classification indicating suitability for curative surgical resection.
3. Adequate organ function as assessed by the investigator before surgery.
4. Provision of written informed consent and willingness to participate in the study.
5. Ability and willingness to comply with study procedures and follow-up requirements.
6. ECOG performance status of 0-1.
7. Absence of distant metastasis confirmed by preoperative thoracoabdominal and pelvic CT or PET-CT.
Exclusion Criteria:
1. Patients with body mass index (BMI) \<18.5 kg/m² or BMI ≥35 kg/m².
2. Patients with severe cardiac, pulmonary, neurological, hepatic, or renal diseases that may prevent tolerance of surgery or anesthesia.
3. Patients unable to tolerate pneumoperitoneum or considered by the investigator to have extensive intra-abdominal adhesions or other conditions preventing safe establishment of pneumoperitoneum.
4. Patients with severe coagulation disorders that contraindicate minimally invasive surgery.
5. Patients with active pulmonary tuberculosis.
6. Patients with severe uncontrolled diseases, acute infections, severe physical deterioration, massive ascites, active intra-abdominal bleeding, or shock.
7. Patients with metastatic lymph nodes fused together or encasing major blood vessels, making curative resection infeasible.
8. Patients with previous abdominal/pelvic surgery, radiotherapy, or chemotherapy that may affect the feasibility of laparoscopic or robotic surgery.
9. Pregnant or breastfeeding women.
10. Patients currently participating in other clinical trials involving investigational drugs or medical devices.
11. Patients considered unsuitable for this study by the investigator.
💊
What it tests
- Robotic-assisted radical resection for Siewert type II/III gastroesophageal junction cancer
First Hospital of Jilin Universiry
Changchun, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
HealthTeky